Small-molecule dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/β-catenin/TCF/LEF signaling. FH535 inhibits recruitment of the coactivators β-catenin and GRIP1, but not the corepressors NCoR and SMRT. FH535 is selectively toxic to carcinomas expressing the Wnt/β-Catenin pathway, and known to inhibit invasion, migration, and growth in vitro in multiple types of cancer, such as liver cancer and triple negative breast cancer cell lines; water soluble sodium salt form of FH535 (Axon 2686).

KEYWORDS: FH535 sodium salt | supplier | Dual Wnt/β-catenin and PPAR inhibitor | FH-535 sodium salt | FH 535 sodium salt | CAS [108409-83-2] | Metabolism | PPARγ | PPARδ | peroxisome proliferator–activated receptor | Nuclear | NR1C | Tcf/Lef